NCT02978235 is a Phase 1 clinical trial of TAS4464 in Multiple Myeloma, sponsored by Taiho Oncology, Inc..

Who is sponsoring NCT02978235?

NCT02978235 is sponsored by Taiho Oncology, Inc..

What drugs are being tested in NCT02978235?

Interventions in NCT02978235: TAS4464.

What condition does NCT02978235 study?

NCT02978235 studies Multiple Myeloma, NonHodgkin Lymphoma.

Is NCT02978235 still recruiting?

NCT02978235 is currently terminated. Last updated 5 September 2024.

Last reviewed 2024-09-05 · How we verify

NCT02978235

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma

Terminated Phase 1 Last updated 5 September 2024

What this trial tests

Phase 1 trial testing TAS4464 in Multiple Myeloma in 11 participants. Terminated before completion.

Timeline

1 March 2017

Primary endpoint
1 February 2018

1 February 2018

Quick facts

Lead sponsor	Taiho Oncology, Inc.
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 March 2017
Primary completion	1 February 2018
Estimated completion	1 February 2018
Sites	7 locations across United States

Drugs / interventions tested

TAS4464 — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →
NonHodgkin Lymphoma — all drugs for NonHodgkin Lymphoma →

Sponsor

Taiho Oncology, Inc. — full company profile →

Who can join

18 and older, any sex, with Multiple Myeloma or NonHodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Phase 1 portion of this study will determine the safety of TAS4464 and the most appropriate dose for patients with Multiple Myeloma or Lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164
Protein neddylation and its role in health and diseases.
Zhang S, Yu Q, Li Z, Zhao Y, et al · · 2024 · cited 97× · PMID 38575611 · DOI 10.1038/s41392-024-01800-9
Anticancer drug discovery by targeting cullin neddylation.
Yu Q, Jiang Y, Sun Y. · · 2020 · cited 62× · PMID 32528826 · DOI 10.1016/j.apsb.2019.09.005
Targeting NEDD8-activating enzyme for cancer therapy: developments, clinical trials, challenges and future research directions.
Fu DJ, Wang T. · · 2023 · cited 45× · PMID 37525282 · DOI 10.1186/s13045-023-01485-7
Chromatin-Bound Cullin-Ring Ligases: Regulatory Roles in DNA Replication and Potential Targeting for Cancer Therapy.
Jang SM, Redon CE, Aladjem MI. · · 2018 · cited 34× · PMID 29594129 · DOI 10.3389/fmolb.2018.00019
Harnessing DNA Replication Stress for Novel Cancer Therapy.
Zhu H, Swami U, Preet R, Zhang J. · · 2020 · cited 30× · PMID 32854236 · DOI 10.3390/genes11090990
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target.
Verzella D, Cornice J, Arboretto P, Vecchiotti D, et al · · 2022 · cited 23× · PMID 36140335 · DOI 10.3390/biomedicines10092233
Novel Agents in Multiple Myeloma.
Szalat R, Munshi NC. · · 2019 · cited 21× · PMID 30694859 · DOI 10.1097/ppo.0000000000000355

Verify or expand the search:

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Taiho Oncology, Inc. trials

Trials by the same sponsor.

NCT07128199 — A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Sta · Phase 3 · recruiting
NCT05973773 — REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) · Phase 3 · active not recruiting
NCT05967689 — A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR · Phase 2 · recruiting
NCT05765734 — A Study of TAS3351 in NSCLC Patients With EGFRmt · Phase 1 · terminated
NCT05403450 — A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Partici · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02978235 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Taiho Oncology, Inc.
Last refreshed: 5 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02978235.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing